Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (411-420 of 1,833) with videos related to

Pageof 184
Sort By:
Mabs|February 26, 2026
A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHORajesh K Mistry, Chendi Nui, Giulia Lambiase, et al.
Mabs|March 10, 2026
Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinomaDanlin Yang, Neha Kamran, Gururaj Shivange, et al.
Mabs|June 4, 2025
Higher order receptor clustering due to the IgG3 subclass is necessary for TLR4 signaling and tolerance induction by novel human anti-TLR4 antibodiesLuke S Heuer, Nicolle Sweeney, Manuel Rojas, et al.
Mabs|May 25, 2025
Data-driven analyses of human antibody variable domain germlines: pairings, sequences and structural featuresClarissa A Seidler, Vera A Spanke, Jakob Gamper, et al.
Mabs|May 4, 2026
Structure-function analysis of empasiprubart, a calcium- and pH-dependent clinical phase complement C2 blocking antibodyLaura Bracke, Heidi Gytz Olesen, Erwin Pannecoucke, et al.
Mabs|March 25, 2026
Optimizing human FcRn mouse models to improve pharmacokinetic evaluation of antibody drug candidatesGregory Christianson, Zachary M Howard, Samantha Kenney, et al.
Mabs|May 8, 2026
A comprehensive evaluation of the human Tg32 and Tg276 FcRn transgenic mouse and non-human primate models for predicting antibody pharmacokinetics in humanMonika Gajewska, Michael Kiffe, Claudio Calonder, et al.
Mabs|May 21, 2026
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trialDirk van Lier, Louis Mourisse, Hákon Hollander, et al.
Mabs|June 4, 2026
Generation of human sequence antibodies in OmniChicken against the highly conserved mammalian target BDNF using three distinct discovery workflowsKathryn H Ching, Sinéad Keating, Baisen Zeng, et al.
Mabs|June 11, 2026
Discovery and optimization of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor for the treatment of hemophilia A and BMacy Jin, Sunita Hett, Reema Jasuja, et al.
Pageof 184

Showing results (411-420 of 1,833) with videos related to

Sort By:
Pageof 184
Mabs|February 26, 2026
A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHORajesh K Mistry, Chendi Nui, Giulia Lambiase, et al.
Mabs|March 10, 2026
Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinomaDanlin Yang, Neha Kamran, Gururaj Shivange, et al.
Mabs|June 4, 2025
Higher order receptor clustering due to the IgG3 subclass is necessary for TLR4 signaling and tolerance induction by novel human anti-TLR4 antibodiesLuke S Heuer, Nicolle Sweeney, Manuel Rojas, et al.
Mabs|May 25, 2025
Data-driven analyses of human antibody variable domain germlines: pairings, sequences and structural featuresClarissa A Seidler, Vera A Spanke, Jakob Gamper, et al.
Mabs|May 4, 2026
Structure-function analysis of empasiprubart, a calcium- and pH-dependent clinical phase complement C2 blocking antibodyLaura Bracke, Heidi Gytz Olesen, Erwin Pannecoucke, et al.
Mabs|March 25, 2026
Optimizing human FcRn mouse models to improve pharmacokinetic evaluation of antibody drug candidatesGregory Christianson, Zachary M Howard, Samantha Kenney, et al.
Mabs|May 8, 2026
A comprehensive evaluation of the human Tg32 and Tg276 FcRn transgenic mouse and non-human primate models for predicting antibody pharmacokinetics in humanMonika Gajewska, Michael Kiffe, Claudio Calonder, et al.
Mabs|May 21, 2026
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trialDirk van Lier, Louis Mourisse, Hákon Hollander, et al.
Mabs|June 4, 2026
Generation of human sequence antibodies in OmniChicken against the highly conserved mammalian target BDNF using three distinct discovery workflowsKathryn H Ching, Sinéad Keating, Baisen Zeng, et al.
Mabs|June 11, 2026
Discovery and optimization of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor for the treatment of hemophilia A and BMacy Jin, Sunita Hett, Reema Jasuja, et al.
Pageof 184